SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

CRMD

CorMedix, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed14d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The Q3 2026 earnings call on November 12 will provide the first complete quarterly financial results and likely more detail on DefenCath utilization trends. The CMS add-on trajectory for 2027 is the key variable for revenue visibility; management's qualitative commentary suggests a non-linear path that depends on CMS's application of utilization data.

DirectionNeutral
Confidencemedium
Horizondays

DefenCath

● Neutral Named in this press release
Impact
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

What to watchDefenCath is already approved and generating revenue, so the next major swing factor is the 2027 Medicare pass-through payment rate, which DaVita warned could drop sharply. Watch for CMS rate-setting updates in early 2027 and the company's Q4 2026 earnings call for 2027 guidance on DefenCath specifically. The Heron acquisition diversifies revenue but adds integration risk.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$5.39
T+0 close · Nov 2, 2026 · via day close
Latest settled
+1.48%
T+5 · $5.47 · next T+20 in 14d
Vs SPY
+1.41%
α at T+5
Latest observation
−12.98%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $5.39entry
  2. T+1 · 14d ago +3.15%α +2.85% · $5.56
  3. T+5 · 8d ago +1.48%α +1.41% · $5.47
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix issued a business update ahead of its Q3 2026 earnings call, reaffirming full-year 2026 revenue guidance of $325M-$345M and reporting $355M cash on hand. The CMS 2027 ESRD final rule set a Q1 2027 DefenCath add-on of $8.32 per session, within the company's previously guided 3x-5x range above the current $2.37 rate, and management provided qualitative commentary on the expected quarterly trajectory of the add-on for 2027.

Key Financial Metrics

Guidance
$325M-$345M
maintained

Key Facts

  • Cash and cash equivalents as of September 30, 2026: approximately $355 million.
  • Full-year 2026 total revenue guidance reaffirmed at $325M-$345M.
  • CMS 2027 ESRD final rule provides a Q1 2027 DefenCath post-TDAPA add-on of $8.32 per dialysis session.
  • Q1 2027 add-on of $8.32 is within the company's previously guided range of 3x-5x higher than the current $2.37 rate.
  • Company anticipates the add-on will decline in Q2 2027 vs Q1, but increase in Q3 and/or Q4 2027 vs Q2.
  • Company believes the average add-on rate for all four quarters in 2027 will exceed 2x the current $2.37 rate.
  • No Q3 2026 financial results were released; the company expects to hold a conference call on November 12, 2026.

Financial Impact

No current-quarter financial results reported. Full-year 2026 revenue guidance reaffirmed at $325M-$345M. Cash balance $355M. The Q1 2027 add-on of $8.32 per session is within prior guidance but the trajectory for subsequent quarters is uncertain.

revenuecash

Risk Factors

  • No Q3 2026 financial results were provided in this update; the earnings call on November 12 may reveal results that differ from expectations.
  • The 2027 add-on trajectory is subject to significant uncertainty, including changes in fee-for-service utilization, pricing, and CMS's calculation methodology.
  • Third-party projections regarding future quarterly add-on adjustments may be unreliable; the company has not endorsed any such projections.
  • Increased dialysis reimbursement may not translate into proportional revenue increases for CorMedix due to pricing pressures and contractual terms.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393044

Track record

21 reports on CRMD

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
  2. Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  3. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  4. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  6. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  7. Nov 2, 202614d ago Press Release Neutral 4/10 Viewing Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
  9. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
  10. Aug 13, 202613w ago 8-K Neutral 5/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026